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Abstract
Improved surgical techniques and greater efficacy of 
new anti-rejection drugs have significantly improved 
the survival of patients undergoing orthotopic liver trans-
plantation (OLT). This has led to an increased incidence 
of metabolic disorders as well as cardiovascular and 
cerebrovascular diseases as causes of morbidity and 
mortality in OLT patients. In the last decade, several 
studies have examined which predisposing factors lead 
to increased cardiovascular risk (i.e. , age, ethnicity, 
diabetes, NASH, atrial fibrillation, and some echo-
cardiographic parameters) as well as which factors 
after OLT (i.e. , weight gain, metabolic syndrome, 
immunosuppressive therapy, and renal failure) are 
linked to increased cardiovascular mortality. However, 
currently, there are no available data that evaluate 
the development of atherosclerotic damage after OLT. 
The awareness of high cardiovascular risk after OLT 
has not only lead to the definition of new but generally 
not accepted screening of high risk patients before 
transplantation, but also to the need for careful patient 
follow up and treatment to control metabolic and 
cardiovascular pathologies after transplant. Prospective 
studies are needed to better define the predisposing 
factors for recurrence and de novo  occurrence of 
metabolic alterations responsible for cardiovascular 
damage after OLT. Moreover, such studies will help to 
identify the timing of disease progression and damage, 
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which in turn may help to prevent morbidity and 
mortality for cardiovascular diseases. Our preliminary 
results show early occurrence of atherosclerotic 
damage, which is already present a few weeks 
following OLT, suggesting that specific, patient-tailored 
therapies should be started immediately post OLT.
Key words: Orthotopic liver transplant; Cardiovascular 
risk; Atherosclerosis, Non-alcoholic fatty liver disease; 
Intima-media thickness; Epicardial fat thickness; 
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Core tip: Due to better immunosuppressive therapies, 
the survival of liver transplantation recipients is 
improved, but an increased incidence of metabolic 
disorders as well as cardiovascular and cerebrovascular 
diseases as causes of morbidity and mortality is 
observed. This review analyzes risk factors [before 
orthotopic liver transplantation (OLT) and occurring 
de novo  after OLT] leading to cardiovascular diseases 
and the current tools to identify high risk patients. 
We also provide preliminary data from one of the first 
prospective studies on the evolution of cardiovascular 
damage in adult patients submitted to OLT.
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EVIDENCE OF CARDIOVASCULAR 
DISEASE IN PATIENTS SUBMITTED TO 
ORTHOTOPIC LIVER TRANSPLANTATION 
Orthotopic liver transplantation (OLT) represents 
the only therapy for several end stage liver diseases 
of different etiology. In Europe as well as in United 
States nearly 6000 patients/year are submitted to liver 
transplantation[1,2].
According to the United Network for Organ Sharing 
registry, the survival rate at 1, 5 and 10 years after 
OLT is respectively of 85%, 70% and 50%[2]. Similarly, 
according to the European Liver Transplant Registry[1], 
the survival rate at 1, 5, 10, 15, 20 years after OLT is 
of 82%, 71%, 61%, 51% and 43%. However, various 
diseases have emerged as possible causes of post OLT 
complications. During the first 6 mo post-transplant, 
the highest risk of death was observed (11% mortality 
rate), while between 6 mo and 8 years post OLT, it 
rated at 2.5%-5%. Such mortality value increased 
again after 8 years to 6%-7%.
In a recent study including 798 transplanted 
subjects followed for a median of 10 years[3], in which 
327 deaths were reported, malignity was the first 
cause of death followed by cardiovascular causes, 
infective diseases and renal failure, accounting for 
22%, 11%, 9% and 6% of death, respectively.
As cardiovascular diseases emerged as a leading 
cause of death, several studies have been proposed in 
order to understand the predisposing factors leading 
to cardiovascular disease, as well as the post-OLT 
conditions facilitating cardiovascular morbidity (de 
novo diseases). However, scanty data are available in 
prospective studies.
RISK FACTORS OF CARDIOVASCULAR 
COMPLICATIONS AFTER OLT
Pre-existing cardio-metabolic pathologies and de novo 
occurrence, partly associated with immunosuppressive 
therapy, are considered the main causes of post-
transplant cardiovascular complications[4]. 
Pre-existing metabolic factors/non-alcoholic fatty liver 
disease
The relevance of cardiometabolic pathologies reflects 
the ongoing epidemic of obesity and diabetes in the 
United States[5,6] and all over the Western countries. 
This is further documented by the marked increase in 
the prevalence of diabetes among candidates to OLT 
independently of etiology. Another metabolic disease 
recently recognized to have a strong role in OLT is 
non-alcoholic fatty liver disease (NAFLD), considered a 
manifestation of the metabolic syndrome (MS) or even 
suggested to precede MS, of which insulin resistance 
is the hallmark. NAFLD is the most frequent cause 
of liver disease in Western countries and is likely to 
become the most common indication for OLT over the 
next decade[7,8].
Non-alcoholic steatohepatitis (NASH) represents 
20%-25% of all NAFLD and may potentially evolve 
to cirrhosis and hepatocellular carcinoma, besides 
carrying all cardiovascular risks typically associated 
to MS[9]. Interestingly, Targher et al[10] reported that 
NASH-affected patients are at increased risk of atrial 
fibrillation, which was recently identified as a severe 
risk factor for OLT[11]. In an analysis performed by 
Van Wagner et al[12], atrial fibrillation was one of the 
factors independently associated with major adverse 
cardiovascular events, especially in patients with 
a previous history of NASH and alcoholic cirrhosis. 
Indeed, a positive history of atrial fibrillation before 
liver transplantation was significantly more frequent 
in patients with major adverse cardiovascular events 
than in those without a previous episode of atrial 
fibrillation
[13]. 
Several studies pointed out the relationship be-
tween NAFLD and cardiovascular mortality in patients 
submitted to OLT. Overweight/obesity, dyslipidemia, 
hypertension and glucose metabolism abnormalities 
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are typical alterations detected with a high frequency 
in patients with NAFLD and they also define MS., 
notably, they have all been associated with high 
morbidity and mortality in patients submitted to 
OLT[14,15]. In addition, patients with NAFLD have been 
reported to be at risk for chronic kidney disease, which 
is another known risk factor for CVD[16,17]. The strong 
association between NAFLD and chronic kidney disease 
suggests that NAFLD could be used to stratify patients 
undergoing liver or kidney transplantation for a better 
evaluation of CV risk[18].
In line with the importance of NAFLD in the history 
of patients undergoing OLT, Laish et al[19] found in 
a retrospective analysis that pretransplant NAFLD, 
body mass index, diabetes, and triglycerides levels 
were predisposing factors for the recurrence of post-
transplant MS and that post-transplant MS was 
associated with cardiovascular morbidity and mortality.
Alteration of glucose metabolism, one of the major 
complications of NAFLD/MS, is already recognized to 
be associated with a worse prognosis (increased risk 
of cirrhosis and hepatocellular carcinoma occurrence) 
in patients with chronic liver disease, independently 
from the etiology (HCV chronic hepatitis, NAFLD). In 
particular, its presence is also associated with a worse 
clinical history of transplanted patients. Several studies 
performed in large cohorts of transplanted patients 
reported that both patients and graft survival was 
negatively associated with pre-existing diabetes or 
with de novo occurrence of diabetes after OLT[20,21]. 
In addition, it has been reported that subjects with 
type 1 diabetes had a significantly lower survival than 
subjects with type 2 diabetes and, in turn the latters 
had a reduced survival compared to patients without 
diabetes[20]. 
The role of diabetes and NAFLD in the natural 
history of OLT is further demonstrated by the evidence 
that patients undergoing OLT for NASH related 
cirrhosis showed significantly higher risk of CVD, 
either in the first 30 d
[22] or within 3 years post OLT, 
compared with patients undergoing transplantation 
for other chronic liver diseases such as primary biliary 
and sclerosing cholangitis[23]. However, overall survival 
did not differ. In addition, a strong association between 
adverse CVD events and post-transplant hypertension 
and diabetes was observed, with a double risk of CVD 
if both comorbidities coexisted. However, conflicting 
data were recently obtained in a large prospective 
study performed in United Kingdom, including almost 
4000 subjects recipients of liver transplant, with 
diabetes having no impact on mortality at any time 
after OLT[24-29]. The Authors have speculated that the 
intensive screenings for cardiovascular complications 
in the diabetic liver transplant candidates of the cohort 
studied could explain these unexpected results. Thus, 
they emphasize the importance of a careful screening 
and selection of the candidates to OLT, of their follow 
up as well as of an active diabetes management after 
transplantation. Such procedures could lead recipients 
with diabetes to have outcomes comparable to those 
of recipients without diabetes.
Although malnutrition is commonly observed in 
patients with end stage liver disease, obesity is a 
metabolic problem that impacts negatively both on 
immediate and long-term survival. Most patients in the 
United States who underwent liver transplantations 
between 1988 and 1996 were overweight, reflecting 
the epidemic of obesity. Obesity was more common 
in women and in patients with cryptogenic cirrhosis, 
suggesting that the so called cryptogenic cirrhosis was 
in truth a metabolic cirrhosis. Severe obesity (BMI > 
40 kg/m2) was associated with decreased 30-d, 1-year, 
and 2-year survival, while five-year survival was 
reduced even in patients with BMI > 35 kg/m2[30]. 
DE NOVO OCCURRENCE OF METABOLIC 
ALTERATIONS AFTER OLT
It is very well known that recurrence or de novo 
occurrence of NAFLD post OLT as well as after kidney 
transplantation may facilitate MS happening[21,31-37]. 
However it is difficult to define the prevalence of 
MS after OLT due to malnutrition, which is usually 
present in most cirrhotic candidates to OLT, and which 
ameliorates after transplantation. This is followed, 
in the first years after OLT, by a marked increase 
in body weight, which in almost 20% of cases 
reaches the level of obesity with an increase of BMI 
of 60%-70% compared to the pretransplant one. 
The increase in weight is almost always associated 
with the development of NAFLD, which in turn is 
accompanied by insulin resistance, the hallmark of 
MS and of NAFLD, present in 20%-58% of cases, 
glucose intolerance/diabetes, altered lipids meta-
bolism in 50%-70%, and very often hypertension in 
60%-70%[21,36,38-41]. Altogether, this also contributes to 
the induction of systemic and renal vasoconstrition, as 
well as impaired sodium excretion when treated with 
immunosuppressive drugs. 
Interestingly, obesity in liver donors is also a 
predictor of liver steatosis in the liver recipients, 
and the presence of steatosis in the donor liver is 
strongly related to decreased allograft function and 
patient survival, with a high probability of NASH 
development. This has led to the decision that grafts 
with steatosis greater than 60% cannot be used for 
liver transplant[22].
New-onset diabetes mellitus, a well described 
complication following solid organ transplantation 
(liver, lung and kidney), occurs in 2% to 53% of 
all solid organ transplants, in 4% to 25% of renal 
transplant recipients and in 2.5% to 25% of liver-
transplants[42-48] and is associated with an increased 
risk of cardiovascular morbidity and infection, as well 
as reduced quality of life, impaired graft function 
and lower patient survival[21,43,48,49]. De novo diabetes 
after OLT has been associated with hepatitis C virus 
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facilitate de novo occurrence of diabetes by decreasing 
insulin production and inducing insulin resistance, 
which is followed by hyperinsulinemia, the effect being 
more severe for tacrolimus. In addition to these effects 
increased oxidative stress and lipid peroxidation also 
occur, followed by hypertension, dyslipidemia and 
kidney damage[36,53-64].
Among other immunosuppressive drugs demon-
strated to exert negative cardiovascular effects is 
sirolimus, which was reported to be complicated 
by serious adverse events including hepatic artery 
thrombosis and wound healing complications within the 
first 30 d after OLT
[65]. Thus, sirolimus was not approved 
in liver transplantation, although recent studies using 
lower doses showed an improved safety profile[66,67]. 
Viceversa, everolimus provides a new therapeutic option 
for liver transplant recipients, when introduced early 
after liver transplantation[68] particularly with respect to 
posttransplant nephrotoxicity and other adverse events 
associated with long- term administration of CNIs. 
Several studies[69-71] showed that hyperlipidemia 
was more frequent in the everolimus-treated patients 
infection, pre-existing NAFLD, increased BMI, use 
of tacrolimus (as opposed to ciclosporine), steroids, 
age, and ethnicity[43,44,50-52]. In kidney transplant 
recipients variables predictors of new onset diabetes 
were similar to those of OLT, being crucial the early 
detection and management. Table 1 lists risk factors 
leading to metabolic syndrome and its different clinical 
manifestations after OLT.
IMMUNOSUPPRESSIVE THERAPY AND 
METABOLIC ALTERATIONS
The use of highly effective anti-rejection medications 
has led to improved survival, albeit with evidence 
of well-recognized side effects such as metabolic 
derangements, and an overall increase in MS and 
insulin resistance after OLT.
Steroids decrease insulin production by beta-
cells, increase gluconeogenesis and reduce glucose 
utilization, thus strongly contributing to the occur-
rence of diabetes and weight gain. Tacrolimus and 
cyclosporine A, the calcineurin inhibitors (CNIs), 
Table 1  Incidence or prevalence of risk factors of the different manifestations of the metabolic syndrome after orthotopic liver 
transplantation
Disease Incidence/prevalence Risk factors Ref.
Diabetes mellitus 9%-21% (incidence) Male gender [65,105-107]
High pre-LT BMI
Family history
Hepatitis C
Older age immunosuppressants rapamycin gene polymorphisms 
TCF7L2 gene polymorphisms (donor)
Hyperlipidemia 45%-69% (prevalence) Diet [38,108-110]
Older age
High BMI
 DM
Renal impairment, immunosuppressants 
low-density lipoprotein receptor gene polymorphism (donor)
Arterial hypertension 60%-70% (prevalence) Obesity [106,111,112]
Older age
Impaired glycemia
Immunosuppressants
Overweight-obesity 24%-31% (prevalence) High BMI before LT [113-116]
Diet
Immunosuppressants 
Metabolic syndrome 40%-60% (prevalence) Older age [33,106,117,118]
Obesity and increased BMI
pre-LT DM
Genetic polymorphisms in the living donor 
High-dosage immunosuppressive drugs
Changes in intestinal microbiota
NAFLD/NASH 18%-100% (incidence of NAFLD in NASH 
and cryptogenic recipients)
DM [18,33,80,119-124]
0%-14% (incidence of NASH in NASH 
and cryptogenic recipients)
Obesity and weight gain, dyslipidemia
10%-40% (incidence of NAFLD in non-
NASH or cyptogenic recipients)
Genetic predisposition (presence of the rs738409-G allele of the 
Patatin-like phospholipase)
Arterial hypertension
Immunosuppressant
pre-LT alcoholic cirrhosis
Liver graft steatosis
NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis.
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than in those treated with CNIs. The relationship 
between dyslipidemia during mTOR inhibitor admini-
stration and cardiovascular outcomes has not been 
systematically evaluated, and thus the clinical effect of 
these adverse events is not fully understood. However, 
the proportion of patients receiving lipid lowering 
treatment was similar when everolimus associated 
to a reduced doses of tacrolimus or the standard-of-
care tacrolimus treatment were given[72]. Furthermore, 
the incidence of cardiovascular events after 24 mo did 
not differ between the two treatment groups[70]. The 
relationship between high rates of dyslipidemia and 
mTOR inhibitor use (sirolimus and everolimus), either 
in conjunction with or instead of CNIs, may be due to 
altered insulin signaling pathways that result in excess 
triglyceride production and secretion. 
Thus, it is evident that the type of immunosup-
pressive therapy may strongly influence the occurrence 
of metabolic complications (Table 2).
NAFLD, A LEADING CAUSE OF OLT, 
ALSO COMPLICATES OLT DUE TO ITS 
FREQUENT RECURRENCE OR DE NOVO 
OCCURRENCE
In the last 10 years a marked increase of OLT for NASH 
cirrhosis was observed while that of HCV remained 
stable[36]. Thus NAFLD is expected to become the most 
Table 2  Most used immunosuppressive drugs and main metabolic side effects
Factor Metabolic consequences Ref.
Steroid Increased fat deposition with truncal fat distribution [36,53-55]
Decreased fat oxidation                             
Increased gluconeogenesis
Obesity
Decreased glucose utilization                
Decreased b-cell insulin production        
Increased proteolysis,
Reduced protein synthesis
Insulin resistance
Diabetes, NAFLD 
Mineralocorticoids effects           
Sodium retention      
Hypertension
Hyperlipemia
Calcineurin inhibitor Tacrolimus: [58-65]
b-cell toxicity
Decreased insulin secretion
Insulin resistance,
Diabetes (more than cyclosporine)
Cyclosporine: 
Decreased energy metabolism and muscle mass obesity
Weight gain
Decreased cholesterol transport into bile hyperlipidemia
Occupy LDL receptor
(more than tacrolimus) 
Renal vasoconstriction
Hypertension
(more than tacrolimus)
mTOR inhibitor Increase insulin response          [68,125-129]
Block b-cell proliferation          
Alter insulin signaling                                     
Decreased diabetes
Increased diabetes
Increased triglyceride production pathways
And secretion
Increased adipose tissue lipase activity        
Hyperlipidemia
Decreased Lipoprotein lipase activity       
Anti-metabolites Mycophenolate mofetil: [145-149]
No nephrotoxity
No effect on lipid profile, hypertention or diabetes mellitus
Azatioprine: 
Vascular calcification           
Arteriosclerosis
Monoclonal antibodies Basiliximab [150]
No nephrotoxity
Rare effect on lipid profile, hypertension and diabetes mellitus
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common indication for OLT over the next decade, 
given that HCV related morbidity will progressively 
decrease. Post-transplant NAFLD can be due to the 
recurrence of pretransplant MS and NAFLD, but often 
develops de novo because of modified metabolic 
conditions and use of the immunosuppressive drugs. 
NAFLD recurrence post-liver transplantation may 
progress to end-stage disease with liver failure and a 
need for retransplantation[73-76]. NAFLD incidence after 
liver transplantation ranges from 18 to 40% and that 
of NASH between 9%-13%. In addition, in patients 
transplanted for cryptogenic cirrhosis, the time-
dependent risk of developing allograft steatosis is 
100% over 5 years[40,75,77,78], indirectly confirming that 
cryptogenic cirrhosis is an evolution of NASH. 
It is also worth noting that genetic background 
seems to play a role in allograft steatosis, since post-
transplant NAFLD risk is linked to a polymorphism in 
adiponectrin (PNPLA3), which mediates triglyceride 
hydrolysis and has been reported to be the strongest 
genetic factor for liver steatosis, independently of 
insulin resistance. This polymorphism has been 
repeatedly reported to be associated with more severe 
fibrosis in patients with NASH and is also associated 
with pre-transplant obesity risk and presence of 
steatosis in the donor graft[79,80].
The natural history of post-transplant de novo 
NAFLD is poorly understood, but it may contribute 
to increased CVD mortality, since NAFLD is an 
independent risk factor for CVD even in non-cirrhotic 
patients[34,77,81].
It is very likely that the mediator of these processes 
is insulin resistance, which is linked to weight gain 
and high-dose steroid use post-transplantation, and 
is reflected by worsening of glucose tolerance, and 
underlies all manifestations of MS[76,81,82]. Overall, the 
main consequences of post-transplant MS appear to 
be NAFLD recurrence/development, higher incidence 
of adverse CVD events, and chronic transplant ne-
phropathy[64].
Taken together, these evidence clearly demonstrate 
that a strict selection of patients with a complete 
cardiovascular assessment is necessary before listing 
patients for OLT in order to optimize resources and 
start early therapy to prevent complications.
CARDIOVASCULAR SCREENING PRE-OLT
In patients with cirrhosis, a clinical syndrome 
named cirrhotic cardiomyopathy has been noticed. 
This pathology is defined as a blunted contractile 
responsiveness to physiologic, pathologic, or phar-
macologic stress and/or altered diastolic relaxation 
with electrophysiological abnormalities but with normal 
increased cardiac output and contractility at rest, in the 
absence of known cardiac disease and irrespective of 
the causes of cirrhosis[83]. Strict diagnostic criteria are 
lacking and this syndrome often goes unrecognized. 
Van Wagner, as previously reported, showed 
that non coronary incidents represent the major 
adverse cardiovascular events after OLT, including 
atrial fibrillation, heart failure, thromboembolism and 
stroke[11]. 
This suggests that some OLT candidates may have 
subclinical CVD and may not be identified as patients 
at high risk when using standard risk algorithms. A 
study designed to evaluate the association between the 
presence of segmental myocardial perfusion defects 
pre-OLT by using myocardial perfusion scintigraphy 
and the occurrence of post-OLT complications and 
1-year mortality after OLT, showed that even the 
presence of a single reversible perfusion defect was 
significantly related to an increased incidence of 1-year 
all-cause mortality. Due to these results the authors 
suggest the use of myocardial perfusion scintigraphy 
in the work up process[84]. Other studies point out 
the attention to pre-transplant pathology detected 
by echocardiography, including valve regurgitation, 
pulmonary artery pressure, right and left ventricular 
size, systolic function and left ventricular ejection 
fraction[85-87]. One study found a positive association 
between left ventricular hypertrophy and post- 
transplant death[85], whereas others yielded conflicting 
results regarding tricuspid regurgitation and post-
transplant death[86,87]. 
Bushyhead et al[88] tried to determine if specific 
findings in pre-transplant echocardiography were 
associated with post-transplant survival and the 
development of cardiovascular and renal disease. 
The results of this study showed that increasing 
pulmonary artery systolic pressure was associated 
with significantly increased risk of hospitalization for 
myocardial infarction or heart failure, while increased 
left ventricular ejection fraction, a possible expression 
of cirrhotic cardiomyopathy, was associated with a 
non-significant increased risk of stage 4 or 5 chronic 
kidney disease.
Thus, because of the high risk of cardiovascular 
complications after OLT, careful preoperative evaluation 
of coronary risk is assessed in every transplant center. 
However, there is not yet a general agreement on a 
standard cardiovascular screening in OLT candidates. 
European guidelines suggest that electrocardiogram 
and echocardiography should be performed in all 
liver transplant candidates. If the patient has multiple 
cardiovascular risk factors, and is older than 50 
years, a more extensive work up has to be assessed, 
including a cardiopulmonary exercise test to uncover 
asymptomatic ischaemic heart disease[89]. If the target 
heart rate is not achieved during a standard exercise 
test, a pharmacological stress test is the test of choice. 
If coronary disease is suspected, coronary angiography 
should be performed[90]. 
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THERAPY AND FOLLOW UP AFTER 
LIVER TRANSPLANTATION 
After OLT, to prevent cardiovascular events it is neces-
sary to plan a follow up and a therapy focused on 
the control of metabolic syndrome manifestations, 
including control of blood pressure, blood glucose, 
lipid levels and weight, in addition to encouraging 
physical activity, and a correct diet. Individualized 
immunosuppressive therapy should also be designed. 
Furthermore, it is important to assess the presence 
of early vascular and cardiac damage, and to re-
cognize their progression by carotid ultrasound and 
echocardiography, in order to be able to start specific 
therapy and prevent CV events in the future. 
Given the high risk of developing NAFLD after OLT, 
therapy to prevent its occurrence and/or to treat it, 
if already developed, should be started. However, 
currently the only exploitable therapy for NAFLD is 
diet (Mediterranean diet is recommended[91]) and 
physical activity, although all available data suggest 
that improving insulin sensitivity could reduce 
the risk of post OLT NAFLD recurrence or de novo 
development. Drugs as thiazolidinediones (PPARγ 
agonist with insulin sensitizing effects), metformin, 
incretin-mimetics (liraglutide), antioxidants (vitamin E), 
angiotensin converting enzyme inhibitors have given 
promising results in patients with NAFLD. Several other 
pharmacological therapies for NAFLD are being studied, 
such as obeticolic (a syntetic farnesoid X receptor 
agonist), n-3 polynsaturated fatty acids (PUFA), and 
novel agents with anti-inflammatory, anti-fibrotic or 
insulin sensitizing properties [dual PPAR ά/δ agonists, 
dual chemokine receptor (CCR)2/CCR5 agonists and 
fatty acid/bile acid conjugates] and antifibrotic anti-lysil 
oxidase-like (anti-LOXL2) monoclonal antibodies[92]. 
While data on pentoxyphilline and orlistat have 
provided limited or inconclusive results, as well as 
those on lipid lowering drugs (ezetimibe and statins), 
no clinical trials have been conducted in the post-
transplantation setting[34,76,82,93,94]. 
Thus, at present the only effective approaches 
for avoiding cardiovascular disease in the post-
transplant setting are to prevent and manage MS 
and its manifestations. Table 3 presents the current 
available therapies to control metabolic syndrome 
manifestations. 
Also renal dysfunction plays a relevant role in 
the occurrence of cardiovascular disease and death 
after transplantation. Therapeutic strategies should 
be focused to minimize renal injury, particularly in 
NAFLD patients, for example, by reducing exposure 
to CNIs[95]. This can be accomplished by reducing 
or withdrawing CNIs after the stable introduction of 
mycophenolate mofetil, introducing non-CNIs-based 
immunosuppressive protocols with mTOR inhibitors 
(sirolimus and everolimus) or reducing the CNIs dose 
in combination with mTOR inhibitors. The use of such 
protocols will require further prospective studies within 
the context of liver transplantation[95].
Problems that remain to be resolved 
The onset of cardiovascular modifications after OLT 
remains poorly understood, the timing in which these 
modifications occur after OLT is still being debated. 
Only a few studies (based on paediatric population 
and prevalently on kidney transplant) and a meta-
analysis[96-103] have shown that after solid organ 
transplantation there was a rapid increase of subclinical 
atherosclerosis evaluated by aortic stiffness and carotid 
intima-media thickness. 
A recent study[104] demonstrated that at 1 year 
post-transplant, independently of the indication to OLT, 
LT recipients have similar pro-atherosclerotic profiles 
as patients with NASH, as measured by endothelial 
biomarkers and inflammatory cytokines, even when 
conventional cardiovascular risk factors, such as 
obesity or elevated Hs-CRP or/and high FRS, are not 
observed. 
OUR PRELIMINARY RESULTS
We are conducting a prospective study aimed to 
understand the types of cardiovascular modifications 
and their time of development after OLT. Seventy-
nine patients in a liver transplant list, were enrolled 
from 2014 and followed for 2 years after transplant. 
In these patients cardiovascular, biochemical and 
anthropometrical parameters were assessed at 
admission to the transplant waiting list, and at 6, 
12, and 18 mo after transplant. The cardiovascular 
study included: evaluation of cIMT, presence of 
plaques by carotid ultrasound, diastolic function (E/
A), interventricular septum, ventricular mass, and 
epicardial fat thickness evaluation by echocardiography. 
Preliminary data showed that cIMT progressively 
increased during follow up, starting as early as the 6th 
month, while prevalence of plaques was similar pre 
and post-transplant. A significant decrease of diastolic 
function (E/A) and an increase of inter-ventricular 
septum was observed from enrollment to 6 mo, 
which then remained stable over time. A progressive 
increase of epicardial fat was observed during follow 
up, while ejection function, and ventricular mass did 
not significantly differ. These preliminary results are 
shown in Figure 1.
It is yet to be determined if different immunosup-
pressive therapies influence these early changes and/
or if other predisposing factors contribute to cardiac 
and vascular damage.
Future research directions that may maximize practical 
impact on the field
OLT candidates and recipients should be carefully 
evaluated and followed up not only for liver, but also 
for metabolic complications, optimizing the follow up 
Pisano G et al . Cardiovascular risk after OLT
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Figure 1  Modification of cardiovascular parameters during follow up: dark grey enrollment, black 6th mo, light grey 12th mo. A: Epicardial adipose thickness 
(EAT) significantly increased from baseline to 6th mo; B: Diastolic function (E/A) worsened significantly from baseline to 6th mo; C: Intima-media thickness (IMT) 
increased significantly from baseline to 6th mo. 
Table 3  Post transplant metabolic syndrome manifestations and their possible therapy
Disease Suggested therapy Contraindicated therapy Ref.
Diabetes mellitus Insuline: in the early post-operative setting Metformin: not usable with renal failure (lactic 
acidosis)
[130-133,151-157]
Life-style modification (diet, physical activity) Thiazolidinediones: may be associated to hepato and 
cardiotoxicity and are adipogenic
Oral hypoglicemic agent (after steroids tapering): Second generation sulfonylureas: determine weight 
gain, hypoglycaemia, may increase CNI level
   Metformin: less weight gain and hypoglicemia Meglitinides: determine weight gain, hypoglycemia 
(only with renal insuff), CNI may increase 
repaglinide level, are expensive
   Thiazolidinediones: well tolerated, may improve 
   post-LT NAFLD 
Alpha-glucosidase inhibitors: determine 
gastrointestinal side effects,are less effective, are 
expensive
   Dypeptyl peptidase-4 (DPP4) inhibitors, well tolerate, 
   no weight gain, no hypoglicemia, potential anti-
   inflammation, antihypertension, antiapoptosis effects 
   and immunomodulation on the heart, vessels, and 
   kidney, independent of their hypoglicemic effect
Selective renal sodium glucose co-transporter 2 
(SGLT 2): dapagliflozin, canagliflozin, empagliflozin, 
well tolerated but reported hepato-toxicity, 
contraindicated in patients with renal impairment
Hyperlipidemia Hypercholesterolemia responds to: Statins (except pravastatin and flestatin) are 
metabolized by cytochrome P-450 3A4, the same that 
metabolize CNIs and sirolimus so they must be used 
with caution because of myotoxicity
[134-138]
   HMGCoA inibitors (statins): pravastatine is the most 
   studied and used but also atorvastatin, simvastatin, 
   lovastatin, cerivastatin and fluvastatin are used
If used with statins fibrates may increase calcineurin 
inibitors levels
   Diet rich in omega 3 fatty acids, fruits, vegetables and 
   dietary fiber
Hypertrigliceridemia responds to:
   Fish oil (omega 3)
   Fibric acid derivates (gemfibrosil, clofibrate, fenofibrate)
Arterial 
hypertension
First line agents: calcium channels blockers (amlodipine, 
isradipine, felodipine)
Nifedipine may increase CNI levels and may cause 
leg edema
[139-141]
Second line agents: specific β-blockers, ACE inibitors, 
angiotensin receptors blockers and loop diuretics
ACE inibitors and angiotensin receptors blockers 
may exacerbate CNI-induced hyperkalemia, but may 
provide anti-fibrotic properties and possibly protect 
against calcineurin induced renal injury
Thiazides and other diuretics must be used with 
close follow-up because of potentiation of electrolyte 
abnormalities, hyperuricemia and renal dysfunction 
Obesity Bariatric surgery: well tolerated and successful but require 
a complex reoperation
Orlistat (tetrahydrolipstatin), inhibitor of pancreatic 
lipase has limited efficacy and possibly interferes 
with immunosuppressive therapy
[141-144]
Gastric banding at the time of liver transplant procedure 
seems successful and well tolerate
Gastric bypass surgery can affect intestinal drug 
absorption
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by introducing blood tests and imaging approaches 
that are able to show early metabolic, cardiovascular 
and atherosclerotic alterations.
New parameters that are able to identify subjects 
at higher metabolic/cardiovascular risk should be 
identified to plan personalized therapy, including 
nutritional rules and physical activity. 
Prospective studies aimed to evaluate the develop-
ment of early atherosclerotic damage are needed 
to understand the timing in which a specific therapy 
should be started.
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